Retatrutide vs Semaglutide: What the Research Shows
Retatrutide and Semaglutide side by side: what they are, how they are regulated and what is still unknown.
Where the research points
Consider Retatrutide if…
- you are weighing an investigational option (no FDA-approved product yet): the TRIUMPH trial reported mean weight change of -25.0% with the 12-mg dose versus -3.9% with placebo[1]
- you want to know where approval stands: Lilly states it plans to submit a Biologics License Application to the FDA, a submission plan and not an approval[18]
Consider Semaglutide if…
- you want an FDA-approved product: Wegovy (semaglutide) is labelled to reduce excess body weight and maintain weight reduction long term in adults with obesity, or with overweight plus a weight-related condition[16]
- you want cardiovascular-outcomes data in obesity without diabetes: The primary cardiovascular composite occurred in 6.5% on semaglutide vs 8.0% on placebo (hazard ratio 0.80, 95% CI 0.72 to 0.90).[17]
- you are tested in sport and want to avoid a WADA-prohibited substance: Retatrutide is prohibited by WADA at all times (check semaglutide's own status separately)[6]
Spec comparison
Showing 8 of 12 fields where the two differ. Category, PCAC vote, Jul 2026, Evidence strength, Named in FDA warning letters, 2026 are the same or both unknown.
| Field | Retatrutide | Semaglutide |
|---|---|---|
| Class | GLP-1 / GIP / glucagon triple agonist | GLP-1 agonist |
| Also called | reta, GLP-3, LY3437943 | sema, Ozempic, Wegovy, Rybelsus, Wegovy pill |
| Category | GLP-1 & metabolic | GLP-1 & metabolic |
| FDA status | Investigational · phase 3 | FDA approved (Ozempic, Wegovy, Rybelsus) |
| PCAC vote, Jul 2026 | Not on the Jul 2026 agenda | Not on the Jul 2026 agenda |
| WADA | Prohibited by WADA (S0)Retatrutide is not named, and GLP-1/amylin class agonists are not listed. But it is an investigational drug with no approval in the sources we reviewed, and S0 prohibits drugs under clinical development that no authority has approved. If it is approved somewhere this would change. | Not on the WADA Prohibited ListGLP-1 and GIP agonists are not named anywhere on the 2026 list. This one is an approved medicine, so the catch-all S0 (which only covers drugs with no approval anywhere) does not apply to it. |
| Half-life | approximately 6 dayssubcutaneous · Lancet 2022, PMID 36354040 | approximately 1 weeksubcutaneous · FDA label (Ozempic) |
| Evidence strength | Human RCT evidence, 4 of 4Strongest: The New England journal of medicine 2026, PMID 42814954 | Human RCT evidence, 4 of 4Strongest: Lancet 2026, PMID 41865758 |
| Human studies we summarised | 11 human (11 randomized or controlled) of 16 summarised | 23 human (19 randomized or controlled) of 27 summarised |
| Typical study doses |
|
|
| Vial sizes sold | 5 mg, 10 mg, 12 mg, 15 mg, 20 mg, 24 mg, 30 mg, 36 mg, 40 mg, 50 mg, 60 mg | 2 mg, 3 mg, 5 mg, 10 mg, 15 mg, 20 mg, 30 mg |
| Named in FDA warning letters, 2026 | Yes (24 Aug 2026; 31 Mar 2026) | Yes (24 Aug 2026; 31 Mar 2026) |
Bracketed values are pending a sourced figure. Legal data reflects the regulatory events in our tracker.
Retatrutide and Semaglutide together
People also search for this pair as a stack. The stack page covers timing and interaction questions as they are sourced. Evidence for the combination: No studies tested these together (PubMed search: 90 results, 2 Oct 2026).
Weight, heart outcomes and the limits of cross-trial reading
In semaglutide's obesity trial, mean body-weight change from baseline to week 68 was -14.9% versus -2.4% on placebo.[15]
In a retatrutide trial, mean percent weight change was -17.6% (4 mg), -23.7% (9 mg) and -25.0% (12 mg) versus -3.9% on placebo.[1]
In a higher-dose semaglutide trial, mean body-weight change was greater on 7.2 mg than on 2.4 mg.[19]
In a semaglutide cardiovascular trial, a primary cardiovascular end-point event occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group (hazard ratio 0.80).[17]
A pooled analysis found retatrutide lowered systolic blood pressure (weighted mean difference -6.79 mmHg).[20]
Approval, schedule and safety signals
Drugs@FDA returns no matches for retatrutide.[21]
The Ozempic label starts at 0.25 mg once weekly and increases to 0.5 mg once weekly after 4 weeks.[10]
The Ozempic label cites a long half-life of approximately 1 week.[10]
In a retatrutide trial, dose-dependent increases in heart rate peaked at 24 weeks and declined thereafter.[22]
The semaglutide label carries a boxed warning: in rodents it causes dose-dependent and treatment-duration-dependent thyroid C-cell tumors.[10]
Common questions
Is retatrutide better than Wegovy?
Retatrutide's trial reported -25.0% at 12 mg against -3.9% on placebo, but semaglutide's results come from different trials, so the figures are not a direct comparison.[1]
Can you switch from semaglutide to retatrutide?
Drugs@FDA returns no matches for retatrutide, so there is no label guidance on switching.[21]
Ozempic or retatrutide: which is safer?
In the retatrutide trial the most common adverse events were gastrointestinal.[1]
Sources
- 1Retatrutide phase 3 TRIUMPH-1 results publishedNEJM (PubMed 42814954) · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 2FDA warning letters to five research-peptide sellersFDA warning letter (NuScience Peptides; 1 of 5) · 2026fda.govAccessed 2 Oct 2026
- 3Eli Lilly sues six retatrutide sellersEli Lilly (press release) · 2026investor.lilly.comAccessed 2 Oct 2026
- 4FDA proposes excluding semaglutide, tirzepatide and liraglutide from the 503B bulks listFDA · 2026fda.govAccessed 2 Oct 2026
- 5Seven FDA warning letters to online sellers of GLP-1 productsFDA warning letter (Gram Peptides; 1 of 7) · 2026fda.govAccessed 2 Oct 2026
- 6World Anti-Doping Code International Standard Prohibited List 2026World Anti-Doping Agency · 2026wada-ama.orgAccessed 2 Oct 2026
- 7LY3437943, a novel triple GIP, GLP-1, and glucagon receptor agonist in people with type 2 diabetes: a phase 1b, multicentre, double-blind, placebo-controlled, randomised, multiple-ascending dose trial.Lancet (London, England) · 2022PMID 36354040Accessed 2 Oct 2026
- 8Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes.Diabetes, obesity & metabolism · 2026PMID 42608321Accessed 2 Oct 2026
- 9Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial.The lancet. Diabetes & endocrinology · 2025PMID 40609566Accessed 2 Oct 2026
- 10These highlights do not include all the information needed to use OZEMPIC ® safely and effectively. See full prescribing information for OZEMPIC. OZEMPIC (semaglutide) injection, for subcutaneous use FDA label (Ozempic), DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 11Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials.Lancet (London, England) · 2026PMID 41865758Accessed 2 Oct 2026
- 12Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis.The New England journal of medicine · 2025PMID 40305708Accessed 2 Oct 2026
- 13Oral Semaglutide at a Dose of 25 mg in Adults with Overweight or Obesity.The New England journal of medicine · 2025PMID 40934115Accessed 2 Oct 2026
- 14PubMed search: (retatrutide[tiab] OR LY3437943[tiab]) AND (semaglutide[tiab] OR Ozempic[tiab] OR Wegovy[tiab] OR Rybelsus[tiab] OR NN9535[tiab])PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
- 15Once-Weekly Semaglutide in Adults with Overweight or Obesity.The New England journal of medicine · 2021PMID 33567185Accessed 2 Oct 2026
- 16WEGOVY prescribing information (FDA label)FDA label, DailyMed · current labeldailymed.nlm.nih.govAccessed 2 Oct 2026
- 17Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.The New England journal of medicine · 2023PMID 37952131Accessed 2 Oct 2026
- 18Official web pageOfficial web page · web page
- 19Once-weekly semaglutide 7·2 mg in adults with obesity (STEP UP): a randomised, controlled, phase 3b trial.The lancet. Diabetes & endocrinology · 2025PMID 40961952Accessed 2 Oct 2026
- 20Effect of Retatrutide, a Novel Triple Receptor Agonist, on Blood Pressure and Lipid Levels: A Systematic Review and Meta-analysis of Randomized Controlled Trials.High blood pressure & cardiovascular prevention : the official journal of the Italian Society of Hypertension · 2026PMID 42371360Accessed 2 Oct 2026
- 21Drugs@FDA (openFDA) search: active ingredient "retatrutide"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026
- 22Triple-Hormone-Receptor Agonist Retatrutide for Obesity - A Phase 2 Trial.The New England journal of medicine · 2023PMID 37366315Accessed 2 Oct 2026
Found an error? Report a correction.